Trials & Filings

Intensity Therapeutics Receives FTD for Breast Cancer Treatment

INT230-6 will be evaluated in patients with relapsed or metastatic triple negative breast cancer

Intensity Therapeutics Inc. announced that the U.S. FDA has granted Fast Track designation to the company’s development program evaluating INT230-6 for the treatment of patients with relapsed or metastatic triple negative breast cancer (TNBC) who have failed at least two prior lines of therapy. “We are extremely pleased to receive this Fast Track designation, which validates the potential of INT230-6 to treat patients with relapsed or metastatic triple negative breast cancer as a single agent...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters